Attention www.globalkeysolutions.net is now www.keypedia.com, read the full press release here.
KeyPedia LogoKeyPedia Icon
  1. Home
  2. /
  3. Records
  4. /
  5. 483
  6. /
  7. Solaris Pharmacy, Inc.
483
•Solaris Pharmacy, Inc.•February 26, 2020

FDA 483 - Solaris Pharmacy, Inc. - February 26, 2020

View on Dashboard

Your cart

Your cart is empty.

Browse public document pages and click Buy this document. We'll ask for your email at checkout, no account needed up front.

Browse documents

Discuss this record with AI

ChatGPT

Claude

Perplexity

Grok

Copilot

Record Details

This FDA Form 483 document details observations from an inspection concerning the manufacturing of non-sterile drug products, specifically capsules for oral use and Budesonide Inhalation Capsules 320mcg.

The primary observation (a) notes that cleaning agents used for equipment and production areas are unsuitable. On February 19, 2020, a non-sterile technician was observed using a cleaning agent intended for non-food surfaces to clean and disinfect a capsule instrument, despite the firm routinely producing capsules for oral administration. Approximately redacted batches of oral drug product capsules were produced using this method since November 1, 2019.

A second observation (b) on the same date involved the use of an expired sterile cleaning agent by a non-sterile technician to clean and sanitize a capsule instrument in the non-sterile compounding room. This instrument is used in the production of Budesonide Inhalation Capsules 320mcg, Lot #1951, with a Beyond Use Date of 08/19/20.

The document also states that "Non-pharmaceutical grade components are not used in the production of your non sterile drug products. Specifically:" but the specific details following this statement are redacted or incomplete in the provided text. The observations indicate deficiencies in cleaning and sanitization procedures and material suitability for drug product manufacturing.

Company
Solaris Pharmacy, Inc.
Inspection Date
February 26, 2020
Product Type
Drugs
Office
Dallas District Office
Person
  • Patty P. Kaewussdangkul (Investigator)
Open in Dashboard

ID · a836ac02-594c-4b5a-b2dd-12bbb9ac7c41

footer
Global Key Solutions
Regulatory Data Transformed
Contact
New York Office:
370 Jay Street 7th Floor
Brooklyn, NY 11201
Scranton Office:
Scranton Enterprise Center, Suite 217
201 Lackawanna Avenue
Scranton, PA, 18503
🇺🇸+1 917-789-5099
🇪🇺+48 532-447-507
info@globalkeysolutions.net
Quick Links
HomePlatform OverviewMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPartners
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026, Global Key Solutions All rights reserved.